SCHEMBL435765

SCHEMBL435765

Cc1cnc2cc(Cl)ccc2c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 2/20 0.57
PDGFRB P09619 1/20 0.54
PDGFRA P16234 1/20 0.54
CCR1 P32246 2/20 0.52
CCR5 P51681 2/20 0.52
CCR8 P51685 2/20 0.52
NR4A2 P43354 2/20 0.50
POLB P06746 1/20 0.43
KMT2A Q03164 3/20 0.42
HRH4 Q9H3N8 2/20 0.41
KDM4E B2RXH2 2/20 0.40
ALDH1A1 P00352 2/20 0.40
LMNA P02545 1/20 0.40
HPGD P15428 1/20 0.40
NFKB1 P19838 1/20 0.40
NFKB2 Q00653 1/20 0.40
RELA Q04206 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
OGA O60502 1/20 0.40
DAO P14920 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL434860 0.84 CYP1A2 (0.57) CYP1A2PDGFRBPDGFRACCR1CCR5
SCHEMBL7157574 0.81 PDGFRB (0.59) CYP1A2PDGFRBPDGFRANR4A2HRH4
SCHEMBL30702581 0.81 PDGFRB (0.59) CYP1A2PDGFRBPDGFRANR4A2HRH4
SCHEMBL7747338 0.81 CYP1A2 (0.63) CYP1A2CCR1CCR5CCR8KMT2A
SCHEMBL13356513 0.76 PDGFRB (0.54) CYP1A2PDGFRBPDGFRANR4A2POLB
SCHEMBL5534628 0.76 CYP1A2 (0.57) CYP1A2CCR1CCR5CCR8KMT2A
SCHEMBL8268977 0.76 ALDH1A1 (0.50) CYP1A2PDGFRBPDGFRAKMT2AKDM4E
SCHEMBL5534632 0.76 ESR2 (0.59) CYP1A2PDGFRBPDGFRACCR1CCR5
SCHEMBL12991057 0.76 CYP1A2 (0.57) CYP1A2PDGFRBPDGFRACCR1CCR5
SCHEMBL16070947 0.76 CYP1A2 (0.57) CYP1A2CCR1CCR5CCR8POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 108 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6472587-B1 PRODUCTION OF A 5-(2-CHLORO-4-(TRIFLUOROMETHYL)PHENOXY)-2-NITROBENZOIC ACID OR 7-CHLORO-3-METHYLLQUINOLINE-8-CARBOXYLIC ACID-TOLERANT PLANT BY EXPRESSING AN EXOGENOUS 5-(2-CHLORO-4-(TRIFLUOROMETHYL)PHENOXY)-2-NITROBENZOIC ACID OR 7-CHLORO-3-METHYLLQUINOLINE-8-CARBOXYLIC ACID-BINDING ANTIBODY IN THE PLANT BASF AKTIENGESELLSCHAFT (DE) 2002-10-29 US claimed
US-4124386-A Color diffusion transfer receiving layer comprising polymeric quaternary n-heterocyclic mordant FUJI PHOTO FILM CO., LTD. (JP) 1978-11-07 US claimed
WO-2024108147-A1 COMPOUNDS, COMPOSITIONS, AND METHODS DENALI THERAPEUTICS INC. (US) 2024-05-23 WO disclosed
EP-3752201-B1 SUSPENSION OF NANOSCALE, ORGANIC PARTICLES AND PROCESS FOR PRODUCTION THEREOF UNIV FRIEDRICH ALEXANDER ER (DE) 2023-11-22 EP disclosed
CN-111936667-B Method for producing laminate 大金工业株式会社 2022-12-13 CN disclosed
WO-2021113698-A1 MASP-2 INHIBITORS AND METHODS OF USE OMEROS CORPORATION (US) 2021-06-10 WO disclosed
US-20200140436-A1 LACTAM-CONTAINING COMPOUNDS AND DERIVATIVES THEREOF AS FACTOR XA INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2020-05-07 US disclosed
US-9975891-B2 Lactam-containing compounds and derivatives thereof as factor Xa inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2018-05-22 US disclosed
US-9975891-B2 Lactam-containing compounds and derivatives thereof as factor Xa inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2018-05-22 US disclosed
US-9655363-B2 Microbiocides SYNGENTA PARTICIPATIONS AG (CH) 2017-05-23 US disclosed
US-9655363-B2 Microbiocides SYNGENTA PARTICIPATIONS AG (CH) 2017-05-23 US disclosed
US-20030181496-A1 Pyrrole derivatives DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2003-09-25 US disclosed
WO-2003047520-A2 SUBSTITUTED AMINO METHYL FACTOR Xa INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2003-06-12 WO disclosed
WO-2003048081-A2 GLYCINAMIDES AS FACTOR XA INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2003-06-12 WO disclosed
EP-1310485-A1 PYRROLE DERIVATIVES SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 2003-05-14 EP disclosed
WO-2003026652-A1 LACTAM-CONTAINING COMPOUNDS AND DERIVATIVES THEREOF AS FACTOR XA INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2003-04-03 WO disclosed
EP-0294685-A2 Process for the preparation of quinolines BASF Aktiengesellschaft (DE) 1988-12-14 EP disclosed
US-4124386-A Color diffusion transfer receiving layer comprising polymeric quaternary n-heterocyclic mordant FUJI PHOTO FILM CO., LTD. (JP) 1978-11-07 US disclosed
US-4021428-A 4-Piperidino-5-oxo-2-pyrazolines FUJI PHOTO FILM CO., LTD. (JA) 1977-05-03 US disclosed
US-3956339-A 4-Pyridinio-5-pyrazolone salts, process for their preparation and their use FUJI PHOTO FILM CO., LTD. (JA) 1976-05-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030181496-A1 Pyrrole derivatives NCOA1, PKD1, NR3C2 CYP1A2 273/4885PDGFRB 131/4885PDGFRA 156/4885
US-20200140436-A1 LACTAM-CONTAINING COMPOUNDS AND DERIVATIVES THEREOF AS FACTOR XA INHIBITORS F12, F2, CPB1 CYP1A2 1188/4885PDGFRB 2382/4885PDGFRA 3201/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.